BACKGROUND: Capecitabine is effective in treating colorectal cancer and is increasingly being investigated for use in preoperative chemoradiation of rectal cancer. Since capecitabine and its metabolites have a plasma half-life of 0.5-1 hour, the relative timing of capecitabine and radiotherapy may affect clinical outcomes. We retrospectively investigated whether the timing of radiotherapy affects rates of acute toxicity, pathologic response, and relapse in rectal cancer patients receiving capecitabine. METHODS: Between June 2001 and July 2004, 111 rectal cancer patients were treated with preoperative radiotherapy and concurrent capecitabine given twice daily, in the early morning and at night. Of these, 44 received at least 70% of their radiation treatments before 12 PM (AM group), and 47 received at least 70% of their radiation treatments after 12 PM (PM group). RESULTS: There were no significant differences between the AM vs. PM groups in rates of grade >/= 2 acute gastrointestinal toxicity (61% vs. 47%) or skin toxicity (23% vs. 26%) or grades >/= 1 hand-foot syndrome (27% vs. 15%). Although the PM group had numerically higher rates of pathologic complete response (28% vs. 16%) and tumor downstaging (57% vs. 39%), differences in these outcomes and in sphincter preservation were not significant. Rates of 2-year local control, distant control, and disease-free survival were nearly identical in the two groups. CONCLUSIONS: No significant differences were seen in the rates of acute toxicity, pathologic response, and relapse between patients in the AM and PM groups. The timing of radiotherapy does not appear to be critical in patients with rectal cancer receiving concurrent capecitabine.
BACKGROUND:Capecitabine is effective in treating colorectal cancer and is increasingly being investigated for use in preoperative chemoradiation of rectal cancer. Since capecitabine and its metabolites have a plasma half-life of 0.5-1 hour, the relative timing of capecitabine and radiotherapy may affect clinical outcomes. We retrospectively investigated whether the timing of radiotherapy affects rates of acute toxicity, pathologic response, and relapse in rectal cancerpatients receiving capecitabine. METHODS: Between June 2001 and July 2004, 111 rectal cancerpatients were treated with preoperative radiotherapy and concurrent capecitabine given twice daily, in the early morning and at night. Of these, 44 received at least 70% of their radiation treatments before 12 PM (AM group), and 47 received at least 70% of their radiation treatments after 12 PM (PM group). RESULTS: There were no significant differences between the AM vs. PM groups in rates of grade >/= 2 acute gastrointestinal toxicity (61% vs. 47%) or skin toxicity (23% vs. 26%) or grades >/= 1 hand-foot syndrome (27% vs. 15%). Although the PM group had numerically higher rates of pathologic complete response (28% vs. 16%) and tumor downstaging (57% vs. 39%), differences in these outcomes and in sphincter preservation were not significant. Rates of 2-year local control, distant control, and disease-free survival were nearly identical in the two groups. CONCLUSIONS: No significant differences were seen in the rates of acute toxicity, pathologic response, and relapse between patients in the AM and PM groups. The timing of radiotherapy does not appear to be critical in patients with rectal cancer receiving concurrent capecitabine.
Authors: Prajnan Das; Edward H Lin; Sumita Bhatia; John M Skibber; Miguel A Rodriguez-Bigas; Barry W Feig; George J Chang; Paulo M Hoff; Cathy Eng; Robert A Wolff; Marc E Delclos; Sunil Krishnan; Nora A Janjan; Christopher H Crane Journal: Int J Radiat Oncol Biol Phys Date: 2006-10-23 Impact factor: 7.038
Authors: J-P Machiels; L Duck; B Honhon; B Coster; J-C Coche; P Scalliet; Y Humblet; S Aydin; J Kerger; V Remouchamps; J-L Canon; P Van Maele; L Gilbeau; S Laurent; C Kirkove; M Octave-Prignot; J-F Baurain; A Kartheuser; C Sempoux Journal: Ann Oncol Date: 2005-10-11 Impact factor: 32.976
Authors: A De Paoli; S Chiara; G Luppi; M L Friso; G D Beretta; S Del Prete; L Pasetto; M Santantonio; E Sarti; G Mantello; R Innocente; S Frustaci; R Corvò; R Rosso Journal: Ann Oncol Date: 2005-11-09 Impact factor: 32.976
Authors: Brian G Czito; Christopher G Willett; Johanna C Bendell; Michael A Morse; Douglas S Tyler; Nishan H Fernando; Christopher R Mantyh; Gerard C Blobe; Wanda Honeycutt; Daohai Yu; Bryan M Clary; Theodore N Pappas; Kirk A Ludwig; Herbert I Hurwitz Journal: J Clin Oncol Date: 2006-02-01 Impact factor: 44.544
Authors: Chris Twelves; Alfred Wong; Marek P Nowacki; Markus Abt; Howard Burris; Alfredo Carrato; Jim Cassidy; Andrés Cervantes; Jan Fagerberg; Vassilis Georgoulias; Fares Husseini; Duncan Jodrell; Piotr Koralewski; Hendrik Kröning; Jean Maroun; Norbert Marschner; Joseph McKendrick; Marek Pawlicki; Riccardo Rosso; Johannes Schüller; Jean-François Seitz; Borut Stabuc; Jerzy Tujakowski; Guy Van Hazel; Jerzy Zaluski; Werner Scheithauer Journal: N Engl J Med Date: 2005-06-30 Impact factor: 91.245
Authors: Jin Cheon Kim; Tae Won Kim; Jong Hoon Kim; Chang Sik Yu; Hee Cheol Kim; Heung Moon Chang; Min Hee Ryu; Jin Hong Park; Seung Do Ahn; Sang-Wook Lee; Seong Soo Shin; Jung Sun Kim; Eun Kyung Choi Journal: Int J Radiat Oncol Biol Phys Date: 2005-10-01 Impact factor: 7.038
Authors: Yeon Joo Kim; Jong Hoon Kim; Chang Sik Yu; Tae Won Kim; Se Jin Jang; Eun Kyung Choi; Jin Cheon Kim; Wonsik Choi Journal: Radiat Oncol J Date: 2017-06-30